USFDA inspection - Alembic Pharmaceuticals Ltd

Code BSE: 533573 NSE:

Alembic Pharmaceuticals Ltd reported successful completion of USFDA inspection at Alembic Pharmaceuticals Limited’ API-III Facility at Karakhadi This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from 17th March, 2025 to 21st March, 2025. Good Manufacturing Practice, GMP inspections are a critical aspect of ensuring the quality and safety of pharmaceutical products. Pharmaceutical companies must approach GMP inspections with careful planning, attention to detail, and a proactive mindset to achieve successful outcomes.